A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults

INTRODUCTION: There is an urgent need for a new and effective tuberculosis vaccine because BCG does not sufficiently prevent pulmonary disease. IMX313 is a novel carrier protein designed to improve cellular and humoral immunity. MVA85A-IMX313 is a novel vaccine candidate designed to boost immunity p...

Descripción completa

Detalles Bibliográficos
Autores principales: Minhinnick, Alice, Satti, Iman, Harris, Stephanie, Wilkie, Morven, Sheehan, Sharon, Stockdale, Lisa, Thomas, Zita-Rose Manjaly, Lopez-Ramon, Raquel, Poulton, Ian, Lawrie, Alison, Vermaak, Samantha, Le Vert, Alexandre, Del Campo, Judith, Hill, Fergal, Moss, Paul, McShane, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786162/
https://www.ncbi.nlm.nih.gov/pubmed/26854906
http://dx.doi.org/10.1016/j.vaccine.2016.01.062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786162/
https://www.ncbi.nlm.nih.gov/pubmed/26854906
http://dx.doi.org/10.1016/j.vaccine.2016.01.062

Ejemplares similares